Thus, it is unlikely that dysregulation of PDE4D could account for the alteration in cAMP levels seen in multiple tissues in FXS, nor is treatment with BPN14770 likely to normalize cAMP levels in all tissues. This evidence concerns the gene PDE4D and fragile X syndrome.